|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||
| 化学式 | C10H8N2O2S |
||||||
| 分子量 | 220.25 | CAS No. | 1198097-97-0 | ||||
| Solubility (25°C)* | 体外 | DMSO | 44 mg/mL (199.77 mM) | ||||
| Water | Insoluble | ||||||
| Ethanol | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | Mirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity. Mirin inhibits MRN-dependent activation of ATM. |
|---|---|
| in vitro | Mirin inhibits DSB-induced ATM activation, the ATM-dependent phosphorylation of the downstream targets Nbs1 and Chk2 and the MRN-dependent autophosphorylation of ATM at Ser1981 in response to DSBs. This compound also inhibits the G2 checkpoint in TOSA4 cells, and homology-dependent DNA repair in HEK293 cells. [1] In cells with integrated HPV16 (SiHa), it sensitizes HPV episomes to PA25 resulting in a ∼5-fold reduction of the PA25 IC50. [2] Pretreatment with this chemical also decreases cell viability and inhibits proliferating cell nuclear antigen expression in cisplatin-treated human embryonic kidney 293 cells. [3] |
| in vivo | Mirin in nanoparticles resulted in a sharp impairment of tumor growth, associated with DDR activation, p53 accumulation, and cell death. |
| キナーゼアッセイ | Nuclease assay | |
|---|---|---|
| Reactions with oligonucleotide nonhairpin substrates contains 25 mM MOPS (pH 7.0), 60 mM KCl, 0.2% Tween 20, 2 mM DTT, 1 mM or 5 MnCl2 (or 5 mM MgCl2, or 5 mM CaCl2), 0.1 pmol of DNA substrate, and 0.3 pmol of Mre11 (or an equivalent amount of Mre11 complexed with Rad50) in a volume of 10 μl, and are incubated at 37°C for 30 min. SDS, EDTA, and proteinase K are then added to final concentrations of 0.2%, 5 mM, and 0.1 mg/ml, respectively, and incubated for another 15 min. 4 μl of each reaction is mixed with 4 μl of formamide loading buffer, and then loaded onto a sequencing gel containing 10% acrylamide and 7 M urea. After the run, each gel is analyzed using a phosphorimaging system. Reactions containing hairpin substrates are identical to those with nonhairpin substrates except that 3 pmol of this compound is added to reactions as indicated, and the reactions are incubated at room temperature overnight. Nonhomologous end-joining reactions contains 25 mM MOPS (pH 7.0), 60 mM KCl, 0.2% Tween 20, 2 mM DTT, 4 mM MgCl2, 2 mM MnCl2, 0.5 mM ATP, 4 ng of plasmid DNA, 10% polyethylene glycol, 0.01 pmol of human DNA ligase I, and 0.06 pmol of this chemical or 0.1 units of E. coli exonuclease III (GIBCO-BRL), in a volume of 10 μl. After incubation at 37°C for 25 min, Tween 20 is added to a final concentration of 0.5%, and a 2.5 μl aliquot is amplified by PCR using primers DAR5 and DAR147. PCR products are cloned using the TA cloning kit and sequenced using an automated ABI Capillary Genetic Analyzer. | ||
| 細胞アッセイ | 細胞株 | HEK 293 cells |
| 濃度 | 100 μM | |
| 反応時間 | 24 h | |
| 実験の流れ | Human embryonic kidney (HEK) 293 cells are maintained in RPMI-1640 supplemented with 5% heat-inactivated fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 mg/mL) in humidified air with 5% CO2 at 37 °C. Cells are given fresh medium at 48 h intervals. The cells are seeded in 96-well plates in regular growth medium. Cells are pretreated with mirin (100 μM for 1 h before the cisplatin (20 μM) treatment followed by incubation for 8 and 24 h. The MTT assay is performed using the EZ-Cytox cell viability assay kit according to the manufacturer's protocol and MTT reduction is measured at a 450 nm wavelength using a micro-plate reader. |
|
| 動物実験 | 動物モデル | Female BALB/c nude mice |
| 投薬量 | 50 mg/kg | |
| 投与方法 | ||
|

Data from [Data independently produced by , , Aging, 2018, 10(4):549-560]

Data from [Data independently produced by , , DNA Repair, 2018, 70:67-71]
| Inherited deficiency of DIAPH1 identifies a DNA double strand break repair pathway regulated by γ-actin [ Nat Commun, 2025, 16(1):4491] | PubMed: 40368919 |
| Genome rearrangements induced by the stimulation of end-joining of DNA double strand breaks through multiple phosphorylation of MRE11 by the kinase PKB/AKT1 [ Nucleic Acids Res, 2025, 53(11)gkaf468] | PubMed: 40479710 |
| Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites [ Redox Biol, 2025, 80:103504] | PubMed: 39879737 |
| PARP10 promotes the repair of nascent strand DNA gaps through RAD18 mediated translesion synthesis [ Nat Commun, 2024, 15(1):6197] | PubMed: 39043663 |
| The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex [ Mol Cell, 2024, S1097-2765(24)00285-5] | PubMed: 38703770 |
| Replication fork stalling in late S-phase elicits nascent strand degradation by DNA mismatch repair [ Nucleic Acids Res, 2024, gkae721] | PubMed: 39180395 |
| CAF-1 promotes efficient PrimPol recruitment to nascent DNA for single-stranded DNA gap formation [ Nucleic Acids Res, 2024, gkae1068] | PubMed: 39558157 |
| SNF2L suppresses nascent DNA gap formation to promote DNA synthesis [ Nucleic Acids Res, 2024, gkae903] | PubMed: 39413208 |
| Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks [ Oncogene, 2024, 43(32):2475-2489] | PubMed: 38961202 |
| RHOJ controls EMT-associated resistance to chemotherapy [ Nature, 2023, 616(7955):168-175] | PubMed: 36949199 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。